NCT02029690View on ClinicalTrials.gov

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

PHASE1TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 23, 2014

Primary Completion Date

August 15, 2018

Study Completion Date

June 30, 2020

Conditions
Pleural Mesothelioma Malignant AdvancedPeritoneal Mesothelioma Malignant AdvancedNon-squamous Non-small Cell Lung CarcinomaUveal MelanomaHepatocellular CarcinomaGliomaSarcomatoid Carcinoma
Interventions
DRUG

ADI-PEG 20

Trial Locations (4)

55902

Mayo Clinic Rochester, Rochester

EC1M 6BQ

Centre for Experimental Cancer Medicine (CECM), London

CB2 0QQ

Cambridge Hospital, Cambridge

SE1 7EH

Guys Hospital, London

Sponsors

Lead Sponsor

Polaris Group
All Listed Sponsors
lead

Polaris Group

INDUSTRY